The UK Competition and Markets Authority (“CMA”) recently published its infringement decision of 7 December 2016 that imposed a fine on Pfizer and Flynn Pharma (“Flynn”) for abusing their respective dominant positions by...more
9/22/2017
/ Abuse of Dominance ,
Antitrust Investigations ,
Appeals ,
Cancer ,
Drug Pricing ,
Excessive Pricing ,
Fines ,
Infringement ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
National Health Service Corp (NHSC) ,
Pfizer ,
Pharmaceutical Industry ,
Prescription Drugs ,
UK ,
UK Competition and Markets Authority (CMA)